Cannabis for Epilepsy

Epilepsy: Pathophysiology and Treatment Landscape

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures resulting from abnormal, synchronized neuronal firing. It affects approximately 50 million people worldwide (WHO) — making it one of the most prevalent neurological conditions globally. In the United States, around 3.4 million people have active epilepsy per the CDC, with approximately 470,000 of those being children.

Seizures arise when the normal balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission is disrupted, leading to paroxysmal, high-frequency neuronal discharges that propagate through neural networks. The clinical manifestation depends on the origin and spread: focal seizures originate in one hemisphere, generalized seizures involve both hemispheres simultaneously. Seizure types include tonic-clonic (grand mal), absence, myoclonic, atonic, and focal aware/unaware variants.

Despite over 30 approved antiepileptic drugs (AEDs), approximately 30% of epilepsy patients have drug-resistant epilepsy — defined as failure of two or more adequately trialed AEDs. This population — representing over 1 million US patients — has the highest medical need and historically the fewest options before considering surgical evaluation. It was precisely in this population (specifically Dravet syndrome and Lennox-Gastaut syndrome, two severe drug-resistant childhood epilepsies) that CBD-based treatment was most intensively studied and ultimately won FDA approval.

Specific Syndromes: Dravet & Lennox-Gastaut

Dravet Syndrome

Dravet syndrome is a catastrophic, genetic epilepsy caused predominantly by mutations in the SCN1A gene encoding the Nav1.1 sodium channel subunit. It begins in the first year of life, typically triggered by fever-associated seizures, and evolves into a severe epileptic encephalopathy with multiple daily seizures, developmental regression, and high SUDEP (sudden unexpected death in epilepsy) risk. Dravet syndrome is notoriously drug-resistant — sodium channel blockers (phenytoin, carbamazepine) are actually contraindicated as they worsen seizures by further impairing Nav1.1 function. Before Epidiolex, the best available treatment involved combinations of valproate, clobazam, and stiripentol, with poor tolerability.

Lennox-Gastaut Syndrome

LGS is a severe childhood epilepsy characterized by multiple seizure types (most notably drop attacks), slow spike-wave discharges on EEG, and intellectual disability. It represents 2–5% of childhood epilepsies but accounts for a disproportionate share of epilepsy-related disability and mortality. Like Dravet, LGS is highly drug-resistant, and the atonic "drop attack" seizures cause frequent, severe injury.

How CBD Works as an Anticonvulsant: Mechanisms

CBD’s anticonvulsant mechanisms are remarkably different from traditional AEDs and are multi-target — which may explain why it works in syndromes resistant to standard drugs:

TRPV1 Desensitization

TRPV1 (transient receptor potential vanilloid 1) channels, when chronically activated by glutamate-driven excitotoxicity, contribute to neuronal hyperexcitability. CBD is a TRPV1 agonist that rapidly desensitizes these channels, reducing their contribution to the excitatory milieu that precedes seizures. This mechanism is particularly relevant in epileptic syndromes with glutamatergic hyperactivity.

GPR55 Antagonism

GPR55 is an orphan G-protein coupled receptor considered a putative "third cannabinoid receptor." Its activation promotes neuronal excitability and potentially lowers the seizure threshold. CBD is a potent GPR55 antagonist — blocking its activity reduces neuronal excitability and may contribute significantly to CBD’s anticonvulsant profile. GPR55 antagonism is distinct from any classical AED mechanism, providing a rationale for CBD’s efficacy in drug-resistant syndromes.

Adenosine Reuptake Inhibition

Adenosine is an endogenous inhibitory neuromodulator that accumulates during high neuronal activity (essentially an endogenous brake on seizure propagation). CBD inhibits the equilibrative nucleoside transporter (ENT1), which normally transports adenosine back into cells. By blocking reuptake, CBD elevates extracellular adenosine, enhancing its seizure-dampening effects. This mechanism may contribute to CBD’s seizure-terminating properties.

Sodium Channel Modulation

CBD modulates voltage-gated sodium channels — the target of many classic AEDs (carbamazepine, phenytoin, lamotrigine). Unlike those drugs, CBD does not worsen Nav1.1 deficiency (the Dravet mutation), making it safe where sodium channel blockers are contraindicated.

Clinical Trial Data

Devinsky et al. (NEJM, 2017) — Dravet Syndrome

This randomized, double-blind, placebo-controlled trial enrolled 120 children and young adults with Dravet syndrome. Patients received CBD (Epidiolex) 20 mg/kg/day or placebo for 14 weeks as add-on to existing AED therapy. Results:

• Median convulsive seizure frequency reduction: 38.9% (CBD) vs. 13.3% (placebo); statistically significant (p=0.01).
• 5% of CBD patients achieved complete seizure freedom vs. 0% placebo.
• Serious adverse events were more common in CBD group (34% vs. 24%), primarily status epilepticus and elevated liver enzymes (particularly in valproate co-medication patients).

Thiele et al. (Lancet, 2018) — Lennox-Gastaut Syndrome

Two large RCTs (GWPCARE3 and GWPCARE4) enrolled over 400 LGS patients. Both CBD doses (10 mg/kg/day and 20 mg/kg/day) significantly reduced drop seizure frequency versus placebo. The lower 10 mg/kg/day dose showed comparable efficacy with better tolerability. FDA approval for LGS followed this data.

Real-World Registry Data (GWPCARE expanded access)

Long-term expanded access program data published in Epilepsia (2019) showed sustained 50%+ seizure reduction in 39–51% of patients over 48 weeks — suggesting durable rather than transient efficacy.

THC Proconvulsant Risk

THC’s effect on seizure threshold is dose-dependent and bidirectional. At very low doses, CB1 receptor activation may have modest anticonvulsant effects by modulating glutamate release. However, high-dose THC — or THC administered to seizure-susceptible individuals — can lower seizure threshold, potentially triggering breakthrough seizures. Case reports of cannabis-precipitated seizures in epilepsy patients predominantly involve high-potency THC products. The clinical consensus is unambiguous: epilepsy patients should not use high-THC cannabis. Pharmaceutical CBD (Epidiolex) or verified high-ratio CBD products (>20:1 CBD:THC, commercially tested) are the only appropriate cannabis-derived interventions.

Protocol Table for Epilepsy

Drug Interactions — Critical Epilepsy Medications

Pediatric Considerations

• Epidiolex approval: Approved for patients 1 year and older. The only cannabis-derived product for which pediatric pharmacokinetic and safety data exist from RCTs.
• Non-pharmaceutical CBD products: Unacceptable for pediatric epilepsy management due to labeling inaccuracies (independent testing shows 43–53% of CBD products inaccurate per label), lack of sterile production, and absence of pediatric dosing studies.
• THC and the developing brain: Absolutely contraindicated. THC dysregulates the developing endocannabinoid system; chronic exposure in children causes lasting cognitive, behavioral, and psychiatric consequences.
• Informed consent: Parents considering Epidiolex should understand the hepatotoxicity risk and importance of LFT monitoring, particularly if the child is on valproate.

Non-Pharmaceutical CBD in Epilepsy: Evidence and Limitations

Before Epidiolex’s FDA approval, many families with drug-resistant childhood epilepsy — particularly those in the Dravet and LGS communities — used non-pharmaceutical, artisanal CBD oils obtained through medical cannabis dispensaries. This created an important body of real-world experience and motivated the formal clinical trials that ultimately produced Epidiolex. However, there are critical distinctions:

• Dosing precision: Epidiolex contains precisely 100 mg/mL CBD with GMP pharmaceutical manufacturing standards. Artisanal CBD oils show significant batch-to-batch variability. Independent testing of consumer CBD products has found 26–40% are under-labeled and 26–53% are over-labeled in CBD content.
• Contaminants: Non-pharmaceutical products may contain residual solvents, pesticides, or heavy metals from extraction processes — unacceptable in epileptic children on complex medication regimens.
• THC presence: Many artisanal "CBD" products contain low but detectable THC; in a child with SCN1A mutation (Dravet), even small amounts of THC may have unpredictable proconvulsant effects.
• Insurance coverage: Epidiolex has FDA approval and is covered by most insurance plans with prior authorization. Artisanal products are not covered and can cost $200–800 per month out-of-pocket.

Bottom line: For pediatric epilepsy, Epidiolex (or its generic equivalent, expected to be commercially available in coming years) is strongly preferred over artisanal CBD products. For adult drug-resistant epilepsy without Epidiolex coverage, verified high-CBD:THC products with batch-tested COAs are a second-line option with medical supervision.

Quality of Life and Non-Seizure Benefits

Beyond seizure frequency reduction, patients in Epidiolex trials reported improvements in quality of life measures that may be clinically independent of seizure control:

• Improved alertness and behavior in Dravet/LGS patients — suggesting CBD may have direct neurodevelopmental benefits beyond anticonvulsant effects
• Reduced caregiver burden, a critical dimension given the devastating daily impact of severe childhood epilepsy on families
• Some patients reported improved sleep, a major quality-of-life factor in epileptic children whose nocturnal seizures severely disrupt family sleep

These non-seizure benefits reinforce Epidiolex’s value even in partial responders — patients who achieve 30–49% seizure reduction (below the 50% response threshold) may still have meaningful quality-of-life improvements worth the continued treatment.

Future Directions: Expanded CBD Applications in Epilepsy

Active research areas include:

• CDKL5 deficiency disorder (CDD): A rare X-linked developmental epilepsy with infantile-onset seizures; early Epidiolex expanded access data showed promise; formal trials ongoing.
• Febrile infection-related epilepsy syndrome (FIRES): A catastrophic new-onset refractory status epilepticus of unclear etiology; case reports of CBD response; no RCT data yet.
• Combination with clobazam: The pharmacokinetic interaction between CBD and clobazam (CBD increases clobazam levels) may actually be therapeutically exploited — some researchers have proposed lower clobazam doses combined with CBD could provide equivalent seizure control with less sedation.
• Synthetic CBD analogs: Research into CBD derivatives with improved BBB penetration, longer half-lives, or reduced CYP450 interaction potential.

Medical Disclaimer

Epilepsy is a serious neurological condition that requires specialist medical care. This page is for educational purposes only. Epidiolex is a prescription medication available only through licensed neurologists and epilepsy specialists. Non-pharmaceutical CBD products should never be used as a substitute for Epidiolex or prescribed AEDs without specialist guidance. Abrupt changes to seizure medication regimens can precipitate life-threatening status epilepticus. Always consult your neurologist before making any changes to epilepsy treatment.